A Review on Primary Angiosarcoma of the Prostate Gland: An Update

Venyo, Anthony Kodzo-Grey (2020) A Review on Primary Angiosarcoma of the Prostate Gland: An Update. In: New Insights into Disease and Pathogen Research Vol. 4. B P International, pp. 90-110. ISBN 978-93-89562-89-7

Full text not available from this repository.

Abstract

Primary angiosarcoma of the prostate (PASOP) is a very rare tumour which most clinicians have not
encountered and may be unaware of. Literature of PASOP was reviewed by obtaining information
from various internet data bases including: Google, Google Scholar, Educus and PUB Med. Less than
20 cases of PASOP have been reported. PASOP may present in a male child or adult with lower
urinary tract symptoms, dysuria, haematuria, pain and constipation. There may be in some cases a
history of prior radiotherapy for adenocarcinoma of prostate. Diagnosis is based upon histological
examination of prostate biopsy specimens which tend to reveal: Proliferative vascular channels that
are lined by atypical multi-layered or atypical solid endothelial cells, variable pleomorphic tumour cells
ranging from spindle cells to large/plump cells; nuclei which are large and pleomorphic and which
contain clumped chromatin and prominent nucleoli; mitotic figures of which some may look atypical
are frequently seen. PASOPs on immunohistochemical staining tend to stain positively for CD34,
Factor 8 (Factor VIII), Vimentin. PASOPs on immunohistochemical staining tend to exhibit negative
staining for PSA, Keratin and S-100. Surgical resection with surgical margins that are clear of tumor
has been shown to be the treatment associated with a chance of long-term survival but a number of
reported cases of PASOP at the time of initial diagnosis had presented with metastatic disease or
locally advanced disease and curative surgery with clear surgical margins has been impossible.
Various adjuvant therapies had been reported but on the whole the prognosis has been poor. There is
on the whole no consensus opinion on the best management options for all stages of the disease.
PASOP is a rare aggressive disease. Clinicians should report cases of PASOP they encounter and
should enter them into a multi-centre trial to find the best treatment option. Perhaps if patients who
develop relapse disease who had previously undergone radiotherapy for prostate cancer undergo
further biopsies of prostate may be new cases of PASOP would be diagnosed in the new biopsy
specimens and this could illustrate that PASOPS are not as uncommon as used to be believed.

Item Type: Book Section
Subjects: Opene Prints > Medical Science
Depositing User: Managing Editor
Date Deposited: 21 Nov 2023 08:42
Last Modified: 21 Nov 2023 08:42
URI: http://geographical.go2journals.com/id/eprint/3149

Actions (login required)

View Item
View Item